• flag
    • flag
    • flag
    • flag
    • flag
    • flag
    • flag
    • flag
  • Have a question? Call us: 
    +1 (800) 472-4508

    Sterigenics International Increases European Ethlyene Oxide Capacity With Expansion At Wiesbaden, Germany Facility



    DEERFIELD, IL, May 10, 2016 – Sterigenics International LLC, the leading global provider of contract sterilization, gamma technologies and medical isotopes, and a portfolio company of Warburg Pincus and GTCR, today announced expansion at their Wiesbaden, Germany location. The expansion will increase ethylene oxide processing capacity by 20 percent and allow for additional future capacity expansion of an additional 20 percent. Construction will be completed by Q1 2017.

    “This expansion represents the continued execution of our growth strategy,” said Michael Mulhern, CEO of Sterigenics International. “We will continue to pursue high impact acquisitions such as the recent addition of Nelson Laboratories, while at the same time, expanding our existing capabilities.”

    “The Wiesbaden expansion is in response to growing demand for ethylene oxide processing in Western Europe,” said Philip Macnabb, President of Sterigenics International. “Wiesbaden has always been a premier facility and this expansion will not only address our short term need, but allow for growth for the future as well. This first part of this expansion will increase capabilities across all phases of the ethylene oxide processing from pre-conditioning, to chamber space and aeration.”

    Opened in 2006, Sterigenics Wiesbaden provides routine ethylene oxide processing, rapid turnaround STAT service, process validation and laboratory testing.

    About Sterigenics International LLC

    Sterigenics International LLC, along with its affiliates, is a global leader in outsourced contract sterilization services, gamma technologies and medical isotopes, and the only vertically integrated sterilization company in the world. Operating out of 48 facilities in 13 countries across the Americas, Europe and Asia, Sterigenics provides contract sterilization and ionization services for the medical device, pharmaceutical, food safety, and high-performance materials industries. Through Nelson Labs, Sterigenics offers microbiological and analytical testing and consultancy to assist customers in developing and maintaining sterilization solutions in medical devices, tissue/implantable products, and pharmaceuticals and biologics fields. Affiliate Nordion positions Sterigenics as the world’s largest provider of Cobalt-60 used in the gamma sterilization process as well as medical isotopes used in the diagnosis and treatment of various diseases and cancers. Sterigenics International LLC and its affiliates serve more than 2,500 customers around the world and is owned by private equity firms Warburg Pincus and GTCR.

    About Warburg Pincus

    Warburg Pincus LLC is a leading global private equity firm focused on growth investing. The firm has more than $40 billion in assets under management. The firm’s active portfolio of more than 120 companies is highly diversified by stage, sector and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised 15 private equity funds, which have invested more than $55 billion in over 750 companies in more than 35 countries. The firm is headquartered in New York with offices in Amsterdam, Beijing, Frankfurt, Hong Kong, London, Luxembourg, Mauritius, Mumbai, San Francisco, São Paulo and Shanghai. For more information, please visit www.warburgpincus.com.

    About GTCR

    Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare, Technology, Media & Telecommunications and Growth Business Services industries. The Chicago-based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $12 billion in over 200 companies. For more information, please visit www.gtcr.com.

    # # #


    John Vita
    John Steven Vita Communications
    +1(847) 853-8283
    [email protected]